Drug Profile


Alternative Names: BDP/FF/GB; Beclometasone dipropionate/formoterol fumarate/glycopyrrolate bromide; Beclometasone/glycopyrrolate/formoterol; CHF 5993 pMDI; CHF-5993; Trimbow

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 27 Nov 2017 Phase-III clinical trials in Chronic obstructive pulmonary disease in Hungary, Belgium (Inhalation) (NCT03268226) (EudraCT2017-000438-79)
  • 04 Sep 2017 Chiesi Farmaceutici plans a phase III trial for Chronic obstructive pulmonary disease (NCT03268226)
  • 24 Jul 2017 Registered for Chronic obstructive pulmonary disease in Liechtenstein, Iceland, Norway, and European Union (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top